Company will measure autonomic and inflammatory signatures in up to 200 critically ill patients using its VITAL^x-patch wearable sensor and ARC cascade-endotyping classifier

LA JOLLA, Calif., Oct. 7, 2026 /PRNewswire/ — InflammaSense, Inc., a pre-revenue medtech company developing wearable autonomic neurography (ANG) technology, today announced its selection as a performer on an Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program receiving up to $38M to transform how clinicians track and treat critical illness in intensive care units. InflammaSense joins the program as a subaward performer under prime awardee the University of Vermont, working alongside UVM’s Gary An on the ReSCUED effort within CIRCLE.

ARPA-H’s CIRCLE program, short for Critical Illness Immunological Reprogramming and Control Point Learning Engine, targets the immune dysregulation that drives organ failure in critically ill patients; sepsis accounts for a substantial share of the roughly 4.6 million Americans who face potentially fatal critical illness each year. The program follows a measure-model-modulate framework: compiling real-time datasets on immune and inflammatory trajectories, building patient-specific computational models, and testing interventions that target immune control points before organ failure progresses.

Under the subaward, InflammaSense will deploy its VITAL^x-patch, a non-invasive wearable sensor, to measure autonomic and inflammatory signatures in up to 200 severely critically ill patients across three clinical sites. Data will feed the company’s Autonomic Research Core (ARC) cascade-endotyping classifier, which stratifies patients by immune trajectory and supports the CIRCLE program’s digital-twin modeling of critical illness. The work builds on InflammaSense’s core platform; it was built on UC San Diego-owned intellectual property covering neural signal detection of immune responses through cervical Autonomic Neurography or “ANG” measured with ventral cervical or anterior neck magnetoneurography and electroneurography.

“CIRCLE gives us a path to validate ANG at scale in the population it was designed to serve,” said Imanuel Lerman, MD, MSc, CEO and Founder of InflammaSense. “Sepsis hyperimmune and or immunoparalysis states are difficult to detect in real time with existing tools; this program will systematically determine whether continuous, non-invasive ANG monitoring can reliably flag that window early enough to act on it.”

About InflammaSense, Inc.

InflammaSense is a pre-revenue medtech company based in La Jolla, California, developing autonomic neurography (ANG) technology for real-time immune monitoring. Its lead indication is sepsis immunoparalysis and sepsis hyperimmune states, paired with matched and targeted therapeutics.

Media Contact:
Imanuel Lerman 
InflammaSense, Inc.
[ilerman@inflammaSense.com] | [619-786-7202]

View original content to download multimedia:https://www.prnewswire.com/news-releases/inflammasense-named-performer-on-arpa-hs-up-to-38-million-circle-award-to-advance-real-time-immune-monitoring-in-critical-care-302900000.html

SOURCE InflammaSense